{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:45:57Z","timestamp":1792640757461,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UIDP\/50026\/2020"],"award-info":[{"award-number":["UIDP\/50026\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000055"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000055"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","award":["UIDB\/50026\/2020"],"award-info":[{"award-number":["UIDB\/50026\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011733","name":"Portuguese League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bioorg.2024.107865","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T19:04:12Z","timestamp":1728500652000},"page":"107865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Chromene-based compounds as drug candidates for renal and bladder cancer therapy \u2013 A systematic review"],"prefix":"10.1016","volume":"153","author":[{"given":"M\u00f3nica","family":"Costa Cerqueira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Martins Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filipa","family":"Pinto-Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e1tima","family":"Baltazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Freitas Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2024.107865_b0005","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"10021","key":"10.1016\/j.bioorg.2024.107865_b0015","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0020","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107865_b0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of Renal Cell Carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0030","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.drudis.2021.07.009","article-title":"Renal cell carcinoma therapy: Current and new drug candidates","volume":"27","author":"Pontes","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"5","key":"10.1016\/j.bioorg.2024.107865_b0035","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"E.G.C.E.a. clinicalguidelines@esmo.org, Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2024.107865_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.870396","article-title":"Advances in Renal Cell Carcinoma Drug Resistance Models","volume":"12","author":"Xiang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2024.107865_b0045","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","article-title":"Bladder cancer","volume":"3","author":"Sanli","year":"2017","journal-title":"Nature Reviews. Dis Primers"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.bioorg.2024.107865_b0055","doi-asserted-by":"crossref","unstructured":"J.A. Witjes, H.M. Bruins, R. Cathomas, E.M. Comperat, N.C. Cowan, G. Gakis, V. Hernandez, E. Linares Espinos, A. Lorch, Y. Neuzillet, M. Rouanne, G.N. Thalmann, E. Veskimae, M.J. Ribal, A.G. van der Heijden, European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines, Eur Urol 79(1) (2021) 82-104.","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"10.1016\/j.bioorg.2024.107865_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2022.100326","article-title":"Socio-economic burden of disease: Survivorship costs for bladder cancer","volume":"32","author":"Michaeli","year":"2022","journal-title":"J. Cancer Policy"},{"issue":"8","key":"10.1016\/j.bioorg.2024.107865_b0065","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1080\/08820139.2022.2118606","article-title":"Immunotherapy for Bladder Cancer: Latest Advances and Ongoing Clinical Trials","volume":"51","author":"Ward Grados","year":"2022","journal-title":"Immun Invest"},{"issue":"19","key":"10.1016\/j.bioorg.2024.107865_b0070","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.2217\/fon-2021-1151","article-title":"Erdafitinib in locally advanced\/metastatic urothelial carcinoma with certain FGFR genetic alterations","volume":"18","author":"Franza","year":"2022","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","article-title":"Mechanisms of immune evasion in bladder cancer","volume":"69","author":"Crispen","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","article-title":"FGFR-TKI resistance in cancer: current status and perspectives","volume":"14","author":"Yue","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2024.107865_b0085","first-page":"350","author":"Hurst","year":"2018","journal-title":"SnapShot: Bladder Cancer, Cancer Cell 34(2)"},{"key":"10.1016\/j.bioorg.2024.107865_b0090","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ejmech.2016.07.057","article-title":"Biological importance of structurally diversified chromenes","volume":"123","author":"Costa","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107865_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133012","article-title":"Synthetic strategies and pharmacological activities of chromene and its derivatives: An overview","volume":"1263","author":"Katiyar","year":"2022","journal-title":"J. Mol. Struct."},{"issue":"8","key":"10.1016\/j.bioorg.2024.107865_b0100","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2174\/0929867053507315","article-title":"Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity","volume":"12","author":"Borges","year":"2005","journal-title":"Curr. Med. Chem."},{"issue":"20","key":"10.1016\/j.bioorg.2024.107865_b0105","doi-asserted-by":"crossref","first-page":"10476","DOI":"10.1021\/cr500075s","article-title":"Natural and synthetic chromenes, fused chromenes, and versatility of dihydrobenzo[h]chromenes in organic synthesis","volume":"114","author":"Pratap","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2024.107865_b0110","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1017\/jns.2016.41","article-title":"Flavonoids: an overview","volume":"5","author":"Panche","year":"2016","journal-title":"J Nutr Sci"},{"key":"10.1016\/j.bioorg.2024.107865_b0115","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/162750","article-title":"Chemistry and biological activities of flavonoids: an overview","volume":"2013","author":"Kumar","year":"2013","journal-title":"Sci. World J."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107865_b0120","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3945\/an.116.012948","article-title":"Flavones: Food Sources, Bioavailability, Metabolism, and Bioactivity","volume":"8","author":"Hostetler","year":"2017","journal-title":"Adv. Nutr."},{"issue":"11","key":"10.1016\/j.bioorg.2024.107865_b0125","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/j.bmcl.2011.03.105","article-title":"Synthesis and in vitro anti-HIV activity of N-1,3-benzo[d]thiazol-2-yl-2-(2-oxo-2H-chromen-4-yl)acetamide derivatives using MTT method","volume":"21","author":"Bhavsar","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107865_b0130","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24091745","article-title":"Novel 6a,12b-Dihydro-6H,7H-chromeno[3,4-c] chromen-6-ones: Synthesis, Structure and Antifungal Activity","volume":"24","author":"Bao","year":"2019","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0135","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharma.2015.07.002","article-title":"Synthesis of new oxadiazole, pyrazole and pyrazolin-5-one bearing 2-((4-methyl-2-oxo-2H-chromen-7-yl)oxy)acetohydrazide analogs as potential antibacterial and antifungal agents","volume":"74","author":"Mahesh","year":"2016","journal-title":"Ann. Pharm. Fr."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107865_b0140","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1021\/acs.jnatprod.9b00113","article-title":"Cytotoxicity and Anti-inflammatory Properties of Apigenin-Derived Isolaxifolin","volume":"82","author":"Chen","year":"2019","journal-title":"J. Nat. Prod."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107865_b0145","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/09168451.2020.1736507","article-title":"Antioxidant activity and absorption of cyanidin-3-O-glucoside liposomes in GES-1 cells in vitro","volume":"84","author":"Quan","year":"2020","journal-title":"Biosci. Biotech. Bioch."},{"key":"10.1016\/j.bioorg.2024.107865_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.foodchem.2020.128482","article-title":"Enzymatic acylation of cyanidin-3-glucoside with fatty acid methyl esters improves stability and antioxidant activity","volume":"343","author":"Zhang","year":"2021","journal-title":"Food Chem."},{"key":"10.1016\/j.bioorg.2024.107865_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175958","article-title":"Antidepressant effects of coumarins and their derivatives: A critical analysis of research advances","volume":"956","author":"Akwu","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"19","key":"10.1016\/j.bioorg.2024.107865_b0160","doi-asserted-by":"crossref","first-page":"7941","DOI":"10.1021\/acs.jmedchem.6b01720","article-title":"Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances","volume":"60","author":"Reis","year":"2017","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2024.107865_b0165","doi-asserted-by":"crossref","first-page":"10996","DOI":"10.1021\/acs.jmedchem.8b00876","article-title":"From Oxiranes to Oligomers: Architectures of U.S. FDA Approved Pharmaceuticals Containing Oxygen Heterocycles","volume":"61","author":"Delost","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107865_b0170","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3389\/fchem.2020.00623","article-title":"2H\/4H-Chromenes-A Versatile Biologically Attractive Scaffold","volume":"8","author":"Raj","year":"2020","journal-title":"Front. Chem."},{"issue":"15","key":"10.1016\/j.bioorg.2024.107865_b0175","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1021\/acs.jmedchem.8b00813","article-title":"Xing, Exploring the Structure-Activity Relationship and Mechanism of a Chromene Scaffold (CXL Series) for Its Selective Antiproliferative Activity toward Multidrug-Resistant Cancer Cells","volume":"61","author":"Bian","year":"2018","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2024.107865_b0180","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1016\/j.bmcl.2016.05.054","article-title":"Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents","volume":"26","author":"Gurrapu","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107865_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173452","article-title":"In vivo efficacy studies of chromene-based compounds in triple-negative breast cancer - A systematic review","volume":"887","author":"Oliveira-Pinto","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0190","doi-asserted-by":"crossref","first-page":"14449","DOI":"10.1038\/s41598-020-71246-w","article-title":"Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin","volume":"10","author":"Lorza","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2024.107865_b0195","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.bioorg.2024.107865_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2021.746430","article-title":"Development of the SciRAP Approach for Evaluating the Reliability and Relevance of in vitro Toxicity Data","volume":"3","author":"Roth","year":"2021","journal-title":"Front Toxicol"},{"issue":"7","key":"10.1016\/j.bioorg.2024.107865_b0205","doi-asserted-by":"crossref","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","article-title":"The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.bioorg.2024.107865_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102020","article-title":"Assessing the reporting quality of early phase dose-finding trial protocols: a methodological review","volume":"60","author":"Villacampa","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bioorg.2024.107865_b0215","doi-asserted-by":"crossref","first-page":"e7586","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107865_b0220","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF01220800","article-title":"Suppression of the proliferation and migration of oncogenic ras-dependent cell lines, cultured in a three-dimensional collagen matrix, by flavonoid-structured molecules","volume":"122","author":"Lu","year":"1996","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0225","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s002800050948","article-title":"In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer","volume":"44","author":"Chien","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107865_b0230","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/carcin\/bgh180","article-title":"Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages","volume":"25","author":"Tyagi","year":"2004","journal-title":"Carcinogenesis"},{"issue":"2\u20133","key":"10.1016\/j.bioorg.2024.107865_b0235","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejphar.2008.11.020","article-title":"Role of cell cycle events and apoptosis in mediating the anti-cancer activity of a silver(I) complex of 4-hydroxy-3-nitro-coumarin-bis(phenanthroline) in human malignant cancer cells","volume":"602","author":"Thati","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107865_b0240","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1742-7843.2010.00613.x","article-title":"Fisetin, a dietary flavonoid, induces cell cycle arrest and apoptosis through activation of p53 and inhibition of NF-kappa B pathways in bladder cancer cells","volume":"108","author":"Li","year":"2011","journal-title":"Basic Clin. Paharmacol. Toxicol."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107865_b0245","first-page":"3599","article-title":"A Dihydroxy-pentamethoxyflavone from <em>Gardenia obtusifolia<\/em> Suppresses Proliferation and Promotes Apoptosis of Tumor Cells Through Modulation of Multiple Cell Signaling Pathways","volume":"30","author":"Phromnoi","year":"2010","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0250","first-page":"125","article-title":"Aryl hydrocarbon receptor activation by aminoflavone: New molecular target for renal cancer treatment","volume":"41","author":"Callero","year":"2012","journal-title":"Int. J. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107865_b0255","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1016\/j.cellsig.2013.08.028","article-title":"Silibinin inhibits beta-catenin\/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness","volume":"25","author":"Wu","year":"2013","journal-title":"Cell. Signal."},{"key":"10.1016\/j.bioorg.2024.107865_b0260","doi-asserted-by":"crossref","unstructured":"L. Gandara, E. Sandes, G. Di Venosa, B. Prack Mc Cormick, L. Rodriguez, L. Mamone, A. Batlle, A.M. Eijan, A. Casas, The natural flavonoid silybin improves the response to Photodynamic Therapy of bladder cancer cells, J Photochem Photobiol B 133 (2014) 55-64.","DOI":"10.1016\/j.jphotobiol.2014.03.006"},{"issue":"2","key":"10.1016\/j.bioorg.2024.107865_b0265","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.lfs.2014.02.002","article-title":"Luteolin sensitizes human 786-O renal cell carcinoma cells to TRAIL-induced apoptosis","volume":"100","author":"Ou","year":"2014","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0270","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3892\/or.2016.4794","article-title":"Isoquercitrin inhibits bladder cancer progression in vivo and in vitro by regulating the PI3K\/Akt and PKC signaling pathways","volume":"36","author":"Chen","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bioorg.2024.107865_b0275","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.biomaterials.2015.11.022","article-title":"Mg(II)-Catechin nanoparticles delivering siRNA targeting EIF5A2 inhibit bladder cancer cell growth in vitro and in vivo","volume":"81","author":"Chen","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.bioorg.2024.107865_b0280","doi-asserted-by":"crossref","first-page":"18642","DOI":"10.1038\/srep18642","article-title":"Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells","volume":"6","author":"Han","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107865_b0285","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3892\/ijo.2017.4089","article-title":"Silibinin suppresses bladder cancer cell malignancy and chemoresistance in an NF-kappaB signal-dependent and signal-independent manner","volume":"51","author":"Sun","year":"2017","journal-title":"Int. J. Oncol."},{"issue":"10","key":"10.1016\/j.bioorg.2024.107865_b0290","first-page":"5709","article-title":"Evaluation of Therapeutic Potential of Phenoxodiol, a Novel Isoflavone Analog","volume":"38","author":"Isono","year":"2018","journal-title":"Renal Cancer Cells, Anticancer Res"},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0295","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17518253.2018.1556743","article-title":"Synthesis and cytotoxic activity of some novel benzocoumarin derivatives under solvent free conditions","volume":"12","author":"Abdel-Aziem","year":"2019","journal-title":"Green Chem. Lett. Rev."},{"key":"10.1016\/j.bioorg.2024.107865_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114620","article-title":"A novel Apigenin derivative suppresses renal cell carcinoma via directly inhibiting wild-type and mutant MET","volume":"190","author":"Li","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107865_b0305","doi-asserted-by":"crossref","first-page":"3846217","DOI":"10.1155\/2022\/3846217","article-title":"HO-1 Contributes to Luteolin-Triggered Ferroptosis in Clear Cell Renal Cell Carcinoma via Increasing the Labile Iron Pool and Promoting Lipid Peroxidation","volume":"2022","author":"Han","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107865_b0310","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bcpt.12229","article-title":"The inhibitory effect of intravesical fisetin against bladder cancer by induction of p53 and down-regulation of NF-kappa B pathways in a rat bladder carcinogenesis model","volume":"115","author":"Li","year":"2014","journal-title":"Basic Clin. Paharmacol. Toxicol."},{"issue":"9","key":"10.1016\/j.bioorg.2024.107865_b0315","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1200\/JCO.1998.16.9.2986","article-title":"Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms","volume":"16","author":"Senderowicz","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2024.107865_b0320","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.2000.18.2.371","article-title":"Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study","volume":"18","author":"Stadler","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2024.107865_b0325","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00280-019-03886-3","article-title":"Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I\/II pilot study","volume":"84","author":"Pintova","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107865_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115323","article-title":"Cisplatin in cancer treatment","volume":"206","author":"Romani","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107865_b0335","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejmech.2018.07.058","article-title":"Exploitation of new chalcones and 4H-chromenes as agents for cancer treatment","volume":"157","author":"Pontes","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107865_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103942","article-title":"Unravelling the anticancer potential of functionalized chromeno[2,3-b]pyridines for breast cancer treatment","volume":"100","author":"Oliveira-Pinto","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107865_b0345","doi-asserted-by":"crossref","unstructured":"T.C. Braga, M.M. Silva, E.O.O. Nascimento, E.C. Dantas da Silva, Y. de Freitas Rego, M. Mandal, Z. Alves de Souza, A.L. Tasca G\u00f3is Ruiz, J. Ernesto de Carvalho, F.T. Martins, I.M. Figueiredo, T. Mendon\u00e7a de Aquino, C. Moreira da Silva, B. Mandal, G. Brahmachari, J.C. Caldas Santos, \u00c2. de F\u00e1tima, Synthesis, anticancer activities and experimental-theoretical DNA interaction studies of 2-amino-4-phenyl-4H-benzo[h]chromene-3-carbonitrile, Eur J Med Chem Rep 4 (2022) 100030.","DOI":"10.1016\/j.ejmcr.2022.100030"},{"key":"10.1016\/j.bioorg.2024.107865_b0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116003","article-title":"Rational design and synthesis of 6-aryl-6H-benzo[c]chromenes as non-steroidal progesterone receptor antagonists for use against cancers","volume":"32","author":"Qin","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2024.107865_b0355","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.bioorg.2024.107865_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179569","article-title":"Curcumin Sensitises Cancerous Kidney Cells to TRAIL Induced Apoptosis via Let-7C Mediated Deregulation of Cell Cycle Proteins and Cellular Metabolism","volume":"23","author":"Obaidi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2024.107865_b0365","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.fct.2019.02.030","article-title":"Auriculasin sensitizes primary prostate cancer cells to TRAIL-mediated apoptosis through up-regulation of the DR5-dependent pathway","volume":"126","author":"Cho","year":"2019","journal-title":"Food Chem. Toxicol."},{"issue":"6","key":"10.1016\/j.bioorg.2024.107865_b0370","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.3892\/ijo.2015.3204","article-title":"Goniothalamin enhances TRAIL-induced apoptosis in colorectal cancer cells through DR5 upregulation and cFLIP downregulation","volume":"47","author":"Sophonnithiprasert","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107865_b0375","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3892\/ijo.2016.3441","article-title":"Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction","volume":"48","author":"Kim","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107865_b0380","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","article-title":"Cell cycle regulation: p53\u2013p21-RB signaling","volume":"29","author":"Engeland","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioorg.2024.107865_b0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2022.146275","article-title":"Silibinin exerts anti-cancer activity on human ovarian cancer cells by increasing apoptosis and inhibiting epithelial-mesenchymal transition (EMT)","volume":"823","author":"Maleki","year":"2022","journal-title":"Gene"},{"issue":"6","key":"10.1016\/j.bioorg.2024.107865_b0390","first-page":"1545","article-title":"Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors","volume":"23","author":"Wu","year":"2010","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.bioorg.2024.107865_b0395","first-page":"1341","article-title":"Silibinin inhibits epithelial-mesenchymal transition of renal cell carcinoma through autophagy-dependent Wnt\/beta-catenin signaling","volume":"45","author":"Fan","year":"2020","journal-title":"Int. J. Mol. Med."},{"issue":"1 Suppl","key":"10.1016\/j.bioorg.2024.107865_b0400","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.bioorg.2024.107865_b0405","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fcell.2017.00018","article-title":"CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells","volume":"5","author":"Senbanjo","year":"2017","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.bioorg.2024.107865_b0410","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/hon.3159","article-title":"A phase 1b study of venetoclax and alvocidib in patients with relapsed\/refractory acute myeloid leukemia","volume":"41","author":"Jonas","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2024.107865_b0415","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1111\/cas.15458","article-title":"Phase I study of alvocidib plus cytarabine\/mitoxantrone or cytarabine\/daunorubicin for acute myeloid leukemia in Japan","volume":"113","author":"Ikezoe","year":"2022","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2024.107865_b0420","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/1078-0432.CCR-20-2649","article-title":"Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia","volume":"27","author":"Zeidner","year":"2021","journal-title":"Clin. Cancer Res."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824007703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824007703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T02:25:00Z","timestamp":1738203900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824007703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":84,"alternative-id":["S0045206824007703"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107865","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chromene-based compounds as drug candidates for renal and bladder cancer therapy \u2013 A systematic review","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107865"}}